Dogwood Therapeutics, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 DWTX Nasdaq Capital Market Check t
• $8,558,712 — ng an aggregate offering price of up to $8,558,712 (the "Shares"). Sales of the Shares, if

Filing Documents

• dwtx-20251128x8k.htm (8-K) — 48KB
• dwtx-20251128xex5d1.htm (EX-5.1) — 21KB
• dwtx-20251128xex10d1.htm (EX-10.1) — 255KB
• dwtx-20251128xex10d1001.jpg (GRAPHIC) — 10KB
• dwtx-20251128xex5d1001.jpg (GRAPHIC) — 4KB
• dwtx-20251128xex5d1004.jpg (GRAPHIC) — 5KB
• 0001104659-25-116865.txt ( ) — 523KB
• dwtx-20251128.xsd (EX-101.SCH) — 3KB
• dwtx-20251128_lab.xml (EX-101.LAB) — 16KB
• dwtx-20251128_pre.xml (EX-101.PRE) — 10KB
• dwtx-20251128x8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade name Northland Capital Markets), as sales agent (the "Sales Agent"), relating to the issuance and sale from time to time by the Company (the "ATM Program"), through the Sales Agent, of shares of the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $8,558,712 (the "Shares"). Sales of the Shares, if any, under the Agreement will be made in sales deemed to be "at-the-market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), as agreed with the Sales Agent. In accordance with the applicable rules of the Securities and Exchange Commission (the "SEC"), as of the date of this Current Report on Form 8-K, the Company is permitted to sell an aggregate of up to $8,558,712 in Shares under the Agreement, which represents 21.38% of the value of the Company's outstanding common stock held by non-affiliates of the Company. The Agreement includes customary representations, warranties and covenants by the Company and customary obligations of the parties and termination provisions. The Company has agreed to indemnify the Sales Agent against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the Sales Agent may be required to make with respect to any of those liabilities. The Company will pay the Sales Agent for sales of its common stock a commission of 3.0% of the gross offering proceeds of the Shares sold through the Sales Agent pursuant to the Agreement. The Shares to be sold under the Agreement, if any, will be issued and sold pursuant to the prospectus forming a part of the Company's shelf registration statement on Form S-3 (File No. 333-287575), which was filed with the SEC on May 23, 2025,

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 5.1* Opinion of Duane Morris LLP 10.1* Equity Distribution Agreement, dated November 28, 2025, by and between Dogwood Therapeutics, Inc. and Northland Capital Markets. 23.1* Consent of Duane Morris LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) * Filed Herewith 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOGWOOD THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Chief Financial Officer, Corporate Secretary and Treasurer November 28, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR